On February 25, 2020 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, reported that Drew Fromkin, President and Chief Executive Officer, will present at the Cowen & Company 40th Annual Health Care Conference, occurring March 2-4, 2020 in Boston (Press release, Tarveda Therapeutics, FEB 25, 2020, View Source [SID1234554748]). Tarveda presentation details:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Monday, March 2, 2020
Time: 12:00pm Eastern Time
Location: Boston Marriott Copley Place, Boston, MA